Suppr超能文献

用 CHO 细胞生产三聚体 SARS-CoV-2 刺突蛋白用于血清学 COVID-19 检测。

Production of trimeric SARS-CoV-2 spike protein by CHO cells for serological COVID-19 testing.

机构信息

Department of Chemical and Biological Engineering, University of Sheffield, Mappin St., Sheffield, UK.

Department of Immunology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

出版信息

Biotechnol Bioeng. 2021 Feb;118(2):1013-1021. doi: 10.1002/bit.27615. Epub 2020 Nov 11.

Abstract

We describe scalable and cost-efficient production of full length, His-tagged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein trimer by Chinese hamster ovary (CHO) cells that can be used to detect SARS-CoV-2 antibodies in patient sera at high specificity and sensitivity. Transient production of spike in both human embryonic kidney (HEK) and CHO cells mediated by polyethyleneimine was increased significantly (up to 10.9-fold) by a reduction in culture temperature to 32°C to permit extended duration cultures. Based on these data GS-CHO pools stably producing spike trimer under the control of a strong synthetic promoter were cultured in hypothermic conditions with combinations of bioactive small molecules to increase yield of purified spike product 4.9-fold to 53 mg/L. Purification of recombinant spike by Ni-chelate affinity chromatography initially yielded a variety of co-eluting protein impurities identified as host cell derived by mass spectrometry, which were separated from spike trimer using a modified imidazole gradient elution. Purified CHO spike trimer antigen was used in enzyme-linked immunosorbent assay format to detect immunoglobulin G antibodies against SARS-CoV-2 in sera from patient cohorts previously tested for viral infection by polymerase chain reaction, including those who had displayed coronavirus disease 2019 (COVID-19) symptoms. The antibody assay, validated to ISO 15189 Medical Laboratories standards, exhibited a specificity of 100% and sensitivity of 92.3%. Our data show that CHO cells are a suitable host for the production of larger quantities of recombinant SARS-CoV-2 trimer which can be used as antigen for mass serological testing.

摘要

我们描述了通过中国仓鼠卵巢(CHO)细胞可扩展且具有成本效益的全长、His 标记的严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)刺突糖蛋白三聚体的生产方法,该方法可用于高特异性和灵敏度地检测患者血清中的 SARS-CoV-2 抗体。通过降低培养温度至 32°C,可显著提高聚亚乙基亚胺介导的人胚肾(HEK)和 CHO 细胞中刺突的瞬时生产(最高增加 10.9 倍),从而延长培养时间。基于这些数据,在强合成启动子的控制下稳定表达刺突三聚体的 GS-CHO 池在低温条件下与生物活性小分子组合培养,可将纯化的刺突产物的产量提高 4.9 倍,达到 53mg/L。通过 Ni-螯合亲和层析对重组刺突进行纯化,最初会得到多种共洗脱的蛋白质杂质,通过质谱鉴定为宿主细胞来源,然后使用改良的咪唑梯度洗脱将其与刺突三聚体分离。纯化的 CHO 刺突三聚体抗原用于酶联免疫吸附测定(ELISA)格式,以检测先前通过聚合酶链反应(PCR)检测到病毒感染的患者队列的血清中的 IgG 抗体,包括那些表现出 2019 冠状病毒病(COVID-19)症状的患者。该抗体检测方法经过 ISO 15189 医疗实验室标准验证,具有 100%的特异性和 92.3%的灵敏度。我们的数据表明,CHO 细胞是生产大量重组 SARS-CoV-2 三聚体的合适宿主,可作为抗原用于大规模血清学检测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验